Trial Profile
A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Indusatumab vedotin (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 11 Feb 2017 Results of interim analysis at the end of stage 1 of the trial published in the Investigational New Drugs.
- 20 Apr 2016 Interim results (n=36) presented at the 107th Annual Meeting of the American Association for Cancer Research
- 04 Mar 2016 There is discrepancy in the status among different EudraCT countries. I have kept the status as per NCT.